Open AccessBioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous Administrations
Author(s) -
Fritz Sörgel,
Ursula ThyroffFriesinger,
Andrea Vetter,
Bernhard Vens-Cappell,
Martina Kinzig
Publication year - 2008
Publication title -
pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.51
H-Index - 59
eISSN - 1423-0313
pISSN - 0031-7012
DOI - 10.1159/000189027
Subject(s) - epoetin alfa , medicine , bioequivalence , pharmacokinetics , confidence interval , pharmacodynamics , clinical endpoint , pharmacology , population , clinical trial , erythropoietin , environmental health
To compare the steady-state pharmacokinetics and pharmacodynamics (PK/PD) of two erythropoesis-stimulating agents (ESA), HX575 (Binocrit, Sandoz GmbH, Holzkirchen, Germany), human recombinant epoetin alfa approved as the first biosimilar ESA, and a comparator epoetin alfa, following multiple subcutaneous administrations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom